ATACANA GROUP Inc.

✨ Holiday Wishes from Atacana: A Season of Gratitude and Giving As we reflect on a year of remarkable growth and resilience, we're excited to celebrate the season with joy and gratitude. We’re honored to have had the opportunity to give back by sponsoring the construction of a school in Laos through Pencils of Promise, helping empower children with the education they need to build brighter futures. From all of us at Atacana Group, we wish you a joyful holiday season, filled with hope, kindness, and exciting new beginnings. May the year ahead bring you continued success and happiness 🫶. #AtacanaGroup #CommunityImpact #Pharma #Biotech #SeasonOfGiving #PencilsOfPromise #happyholidays #seasonsgreetings

✨ Holiday Wishes from Atacana: A Season of Gratitude and Giving As we reflect on a year of remarkable growth and resilience, we're excited to celebrate the season with joy and gratitude. We’re honored to have had the opportunity to give back by sponsoring the construction of a school in Laos through Pencils of Promise, helping empower children with the education they need to build brighter futures. From all of us at Atacana Group, we wish you a joyful holiday season, filled with hope, kindness, and exciting new beginnings. May the year ahead bring you continued success and happiness 🫶. #AtacanaGroup #CommunityImpact #Pharma #Biotech #SeasonOfGiving #PencilsOfPromise #happyholidays #seasonsgreetings

🚀 Unlock the Future of #Antiviral #Vaccines! The antiviral vaccine landscape is entering an exciting era, with game-changing milestones on the horizon for 2025-2026. Leading innovators like Moderna, Pfizer, and GSK are setting the stage with breakthrough regulatory approvals and transformative launches. Here’s a quick snapshot of Key Developments: ✅ Moderna's RSV vaccine approved in Canada ✅ Pfizer's RSV vaccine approved in the US ✅ AstraZeneca's FluMist Quadrivalent now approved for self-administration in the US 🔑 What’s next? We anticipate multiple important milestones for Moderna: five regulatory approvals, four launches, and two data readouts Want to know more about upcoming key catalysts for antiviral vaccines? Comment below 👇to get the link to the full 2025 & 2026 catalysts report. #Vaccines #RSV #Flu #COVID #CMV #Influenza #Moderna #Pfizer #GSK #Sanofi #AstraZenenca #Innovation #CompetitiveIntelligence

✨ Every Friday, our Daily Digest delivers essential insights shaping the future of #neuroscience treatment breakthroughs. Dive into the latest developments you need to know. 🔺Bristol Myers Squibb Enters $1.35 Billion Partnership with BioArctic to Transform Alzheimer's Treatment: This landmark agreement aims to leverage BioArctic's innovative BrainTransporter technology, enhancing drug delivery to the brain and offering new hope for Alzheimer's patients. 🔺Innovative Gene Therapy CAP-002 by Capsida Biotherapeutics Could Be First Disease-Modifying Treatment for STXBP1 Epilepsy: This breakthrough highlights the potential of CAP-002 to address severe neurological conditions, offering hope to patients with high unmet medical needs. 🔺Sangamo Therapeutics, Inc. Secures $20 Million Upfront from Astellas Pharma for Exclusive License on STAC-BBB Technology: The agreement allows Astellas to utilize Sangamo's cutting-edge gene therapy technology, potentially leading to significant advancements in treating neurological disorders. 🔺Vertex Pharmaceuticals Reports Promising Phase 2 Results for Suzetrigine in Painful Lumbosacral Radiculopathy: The investigational NaV1.8 pain signal inhibitor shows a significant -2.02 point reduction in pain scores, advancing to Phase 3 trials. 🔺REXULTI® (brexpiprazole) HCP Approved in Japan for Major Depressive Disorder, Expanding Otsuka Pharmaceutical Companies (U.S.)'s Mental Health Portfolio: This additional indication underscores Otsuka's commitment to providing innovative treatments for mental health challenges, following its successful launch for schizophrenia. 🔺Roche's Parkinson's Drug Prasinezumab Fails to Meet Primary Endpoint in Mid-Stage Trial with Prothena: The Phase IIb PADOVA study results indicate a setback for the collaboration, highlighting ongoing challenges in developing effective treatments for neurodegenerative diseases. 🔺Eli Lilly and Company's Kisunla Secures Key Reimbursement Status in Japan as Country Prepares for New Drug Pricing Reforms: The approval highlights Lilly's commitment to addressing the growing healthcare burden of Alzheimer's disease in Japan's aging population. ----- 💡 Sign up for our Daily Digest to stay updated on the pharma and biotech advancements shaping tomorrow’s healthcare breakthroughs. Don’t miss the insights that could impact your next strategic move! #PharmaDailyDigest #Pharmaceuticals #Biotech #CompetitiveIntelligence #AtacanaGroup #neuro  #neuroscience #Alzheimer’s #Astellas #Vertex #BMS #Roche #Elililly #BioArctic

🚀 Fuel Your Competitive Edge: Accelerate with Precision and Speed with Atacana   In the high-speed world of Pharma, staying ahead requires agility, precision, and the right partner.   Atacana equips you with:   🔥 Predictive Intelligence to stay ahead of the competition and anticipate changes.   🔥 Strategic Support to define winning strategies and action plans.   🔥 AI-Powered Solutions to maximize speed, efficiency and enable access to vast amounts of data.   Let's fast-track your path to success. Drive Your Strategy Forward.   🏅 Ready to lead your team to victory? Contact us at 📥 [email protected]   #AtacanaGroup #Teamwork #Leadership #PharmaStrategy #AIInsights #Innovation

✨ Today’s Pharma Daily Digest delivers critical insights that are reshaping the future of #metabolics and #cardiovascular treatments. Here’s a glance at the biggest developments that you need to know. 🔺Merck Enters $2 Billion Licensing Deal with Hansoh for Innovative Obesity Drug: This strategic partnership includes an upfront payment of $112 million and potential milestone payments of up to $1.9 billion, aimed at tackling the global obesity epidemic. 🔺Gan & Lee Pharmaceuticals Secures FDA Clearance for GZR18 Injection, a Novel Bi-weekly Weight Management Solution: The FDA's approval of GZR18 marks a significant advancement in obesity treatment options, paving the way for a Phase 2 clinical trial against Eli Lilly and Company's Tirzepatide. 🔺Bayer and Evotec Strengthen Alliance to Advance Precision Cardiology: This updated collaboration will leverage innovative disease modeling to identify novel targets for developing effective therapies for cardiovascular diseases. 🔺Novo Nordisk has partnered with Photys Therapeutics in a $186M deal to develop proximity-based therapeutics for cardiometabolic diseases using PHICS technology. Photys will lead preclinical research, while Novo handles clinical development, aiming to expand its pipeline beyond diabetes and obesity by targeting key proteins. 🔺Eli Lilly and Company and EVA pharma plan to deliver affordable insulin to over 1 million people in low- to middle-income countries by 2030. EVA's insulin glargine, approved by the Egyptian Drug Authority, marks its first regulatory milestone. Lilly provides low-cost APIs and supports local production through technology transfer. 🔺Abbott's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker has received FDA approval, marking a significant advancement in cardiac care by targeting the left bundle branch area of the heart. 🔺The FDA approved Impella 5.5 and CP heart pumps for pediatric heart failure and cardiogenic shock. Johnson & Johnson MedTech is partnering with the ACTION network to gather real-world data, advancing care for pediatric heart conditions. ----- 💡 Sign up for our Daily Digest to stay updated on the pharma and biotech advancements shaping tomorrow’s healthcare breakthroughs. Don’t miss the insights that could impact your next strategic move! #PharmaDailyDigest #Pharmaceuticals #Biotech #CompetitiveIntelligence #AtacanaGroup #BMS #Elililly #lilly #Merck #NovoNordisk #Abbott #Bayer

🚀 Explore the newest job openings in Competitive Intelligence for December. The December job listings feature 30 exceptional career opportunities with the leading pharmaceutical companies, including #AstraZeneca, #NovoNordisk, #Abbott, and others. Highlighted below are select positions among the 15 new roles introduced this month: ⚡Global Market Insights, Core Lab and Point of Care. DIA Roche in Zug, Switzerland ⚡Senior Director, Competitive Intelligence – Oncology Gilead Sciences in USA ⚡Senior Director, Competitive Intelligence R&I AstraZeneca in Barcelona, Spain ATACANA GROUP Inc. is a leading Competitive Intelligence Consulting firm that specializes in supporting the pharmaceutical industry. Make the most of these exciting prospects to advance your career in Competitive Intelligence. 📌 Check the first comment below: 👉 Sign up for our monthly newsletter to receive this list directly in your inbox. 👉 Request a PDF copy of this document with links to the hiring companies’ career sites. 📌 Like and share to help connect more people with these valuable opportunities! #pharmaceuticals #hiring #pharma #jobs #Biotech #competitiveintelligence #pharmaindustry #Sanofi #Amgen #AstraZeneca #Roche #Takeda #Abbott #Biogen

✨ Today’s Pharma Daily Digest delivers critical insights that are reshaping the future of #Vaccine and #Respiratory treatments. Here’s a glance at the biggest developments that you need to know.   🔺Positive Phase I Outcomes Propel ENA Respiratory's INNA-051 into Phase II Development: Aiming to Enhance Viral Infection Prevention Strategies. With encouraging results from initial trials, ENA Respiratory is moving forward with INNA-051 into Phase II, focusing on improving prevention strategies against viral infections. 🔺Meijii Seika Pharma Takahashi/Masayuki Celebrates EMA Approval of Kostaive: The European Medicines Agency (EMA) grants approval for Meiji Seika Pharma's Kostaive, a self-amplifying mRNA COVID-19 vaccine targeting the Omicron subvariant JN.1, marking a pivotal advancement in pandemic response efforts. 🔺Merck Aims to Combat RSV with #Clesrovimab: The FDA's acceptance of Merck's BLA for Clesrovimab marks a significant milestone in the fight against RSV, with anticipated availability in time for the 2025-26 RSV season. ----- 💡 Sign up for our Daily Digest to stay updated on the pharma and biotech advancements shaping tomorrow’s healthcare breakthroughs. Don’t miss the insights that could impact your next strategic move! #PharmaDailyDigest #Pharmaceuticals #Biotech #CompetitiveIntelligence #AtacanaGroup #Vaccine #Respiratory #Merck #MeijiSeika #Clesrovimab

🚀 New drug approvals November/December 2024 Innovative new drugs that were approved by FDA or received marketing authorization recommendation by CHMP. This month we highlight: 👉 BridgeBio Pharma’s Attruby/Beyonttra (acoramidis) for the treatment of Wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy. 👉 Galderma’s Nemluvio (nemolizumab) for the treatment of atopic dermatitis. 👉 Geron Corporation’s Rytelo (imetelstat) to treat adult patients with transfusion-dependent anaemia due to very low, low or intermediate risk myelodysplastic syndromes. 👉 Merck’s Welireg (belzutifan) for the treatment of tumours associated with von Hippel-Lindau disease and advanced clear cell renal cell carcinoma A more detailed analysis of these drugs can be found in the attached slides. Subscribe to our Monthly Launch Tracker to be the first to receive these updates. #druglaunch #pharma #pharmaceuticals #biotech #fda #ema #drugapprovals #competitiveintelligence #insights #launchstrategy

✨ Every Tuesday, stay at the forefront of #Oncology advancements! Today’s Pharma Daily Digest delivers essential insights and trends shaping the future of #cancer treatments. 🔺Safety Warning: Carcinogenic Impurities Found in Oncology Drugs highlights the critical need for stringent testing to mitigate cancer risks associated with drug impurities. 🔺Oncology Highlights Collaborative Innovations in Nuclear Medicine Amid Cancer Growth. DeepC and PAIRE unite to integrate AI into nuclear medicine, aiming to improve diagnostic and therapeutic capabilities. 🔺Merck Halts KeyVibe Trials After Futility Analysis Signals Setback in Lung Cancer Research. The discontinuation of Phase 3 trials for vibostolimab and pembrolizumab highlights challenges in advancing effective cancer treatments. 🔺AstraZeneca Collaborates with Tracer Biotechnologies to Enhance Cancer Treatment Monitoring. The agreement will utilize innovative ctDNA detection methods, offering a cost-effective alternative to traditional imaging techniques. 🔺Research at Dana-Farber Reveals CBD May Help Reduce Anxiety in Breast Cancer Patients. While the study did not meet its primary endpoint, findings suggest CBD could lower anxiety levels before diagnostic scans. 🔺FDA Grants Breakthrough Therapy Status to GSK's Jemperli, Showcasing 100% Response Rate in Trials. The designation is based on remarkable early trial results, indicating no evidence of disease in all patients treated. 🔺Merck's KEYTRUDA® (pembrolizumab) HCP® Expands Its Reach: Approved for Early-Stage NSCLC Treatment in China. The National Medical Products Administration grants approval based on promising clinical trial results, marking a milestone in cancer treatment. 🔺NeoPhore Ltd Strengthens Leadership: Michael Shih Appointed CEO Amid Successful Series B Financing. The oversubscribed funding round, backed by Bristol Myers Squibb, positions the company for significant growth in cancer immunotherapy. 🔺Pharmaceutical Industry Commits Over $6 Billion to Molecular Glue Degraders, Paving the Way for Innovative Treatments. The investment reflects a strong belief in the efficacy of molecular glue technology to enhance patient outcomes across various diseases. ----- 💡 Don't forget to sign up for daily updates within the pharma and biotech industry. #PharmaDailyDigest #Pharmaceuticals #Biotech #CompetitiveIntelligence #AtacanaGroup #merck #AstraZeneca #Genmab #Merck #bms